Physician profile
Bindeshwari Sinha
NPI 1760477277
$6,939.49
in general payments reported to CMS, 2019-2025
35 companies · $709 in 2025
The $709 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2020: $776 · 2021: $675 · 2022: $725 · 2023: $1,271 · 2024: $990 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,171.23 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Amarin Pharma, INC. | $813.35 | 2019-2023 | |
| Astellas Pharma US INC | $457.82 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.04 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $418.26 | 2022-2024 | |
| Novo Nordisk INC | $416.86 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Ironwood Pharmaceuticals, INC | $395.88 | 2019 | |
| Lilly USA, LLC | $310.46 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $295.12 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $274.64 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Eisai INC. | $256.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $249.23 | 2019-2025 | |
| Medtronic Vascular, INC. | $175.00 | 2019 | |
| Abbott Laboratories | $168.86 | 2023 | Amplatzer Amulet |
| Janssen Pharmaceuticals, INC | $147.28 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $128.38 | 2020-2022 | |
| Medtronic, INC. | $113.13 | 2024 | Turbohawk |
| Pfizer INC. | $98.87 | 2020-2024 | |
| Edwards Lifesciences Corporation | $92.99 | 2025 | Sapien 3 Ultra Resilia |
| Dexcom, INC. | $78.95 | 2022-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $60.33 | 2023 | Watchman Access System, Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $52.30 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $42.71 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.32 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $34.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $32.67 | 2023 | Quviviq |
| Averitas Pharma INC. | $31.89 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $30.29 | 2021 | |
| Shire North American Group INC | $20.85 | 2019 | |
| Abiomed | $20.69 | 2024 | Impella |
| Clarus Therapeutics INC. | $18.71 | 2021 | |
| Abbvie INC. | $18.26 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.22 | 2024 | Nuzyra |
| Kvk-Tech, INC. | $10.23 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindeshwari Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.